---
title: "Baxter: 70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container — FDA announcement Aug 25, 2026 | Is It on Recall"
description: "Potential presence of particulate matter identified as stainless steel particles in the solution."
url: https://isitonrecall.com/recall/fdapress-6d1b691148d89678-baxter-70-dextrose-injection-usp-in-2000-ml-viaflex-plastic-container/
updated: 2026-10-01
site: "Is It on Recall"
language: en
---

[Recall archive](https://isitonrecall.com/archives/) / FDA company announcement

# Baxter: 70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container — FDA announcement Aug 25, 2026

Published notice; closure not supplied

A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.

Source date Aug 25, 2026. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; [check FSIS directly](https://www.fsis.usda.gov/recalls). [Source coverage and dates](https://isitonrecall.com/sources/).

## What the record says

- **Product**: 70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container
- **Reason**: Potential presence of particulate matter identified as stainless steel particles in the solution.
- **Classification**: Not supplied
- **Recalling firm**: Baxter International Inc.
- **Quantity**: Not supplied
- **Agency-reported status**: Company recall announcement
- **Source record identifier**: 6d1b691148d89678

[Open the official record](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-issues-voluntary-nationwide-recall-one-lot-70-dextrose-injection-due-potential-presence)

## Lot and product identifiers

| Label field | Details supplied by the agency |
| --- | --- |
| Lot, code or applicability | FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution.; The affected lot can be identified by locating the lot number and expiration date on the individual product and shipping carton, as shown in the images below.; Customers should immediately discontinue use of and return all affected units in accordance with their facility’s process. Homecare facilities who used this lot to compound parenteral nutrition solutions should contact their patients to alert them to discontinue using the solutions and replace them with ones not compounded with the affected lot. Baxter is contacting customers by email with instructions on how to identify and return the impacted product.; Product Code \| Product Description \| Lot Number \| Expiration Date \| NDC Number; 2B0296H \| 70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package, Not for Direct Infusion \| Y495066 \| 31-Jul-2027 \| 0338-0719-06 |

Match all identifying details in the current notice. A brand name alone is not enough.

## Product tables from the announcement

These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.

**FDA company announcement, table 1**

| Product Code | Product Description | Lot Number | Expiration Date | NDC Number |
| --- | --- | --- | --- | --- |
| 2B0296H | 70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package, Not for Direct Infusion | Y495066 | 31-Jul-2027 | 0338-0719-06 |

Announcement retrieved Oct 1, 2026. [Official announcement](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-issues-voluntary-nationwide-recall-one-lot-70-dextrose-injection-due-potential-presence).

## Distribution

Not supplied

No US distribution state could be established from this record. Check the official notice.

## Dates in the source

- **Fda listing date**: Aug 25, 2026
- **Company announcement date**: Aug 25, 2026

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

## What to do next

Customers should immediately discontinue use of and return all affected units in accordance with their facility’s process. Homecare facilities who used this lot to compound parenteral nutrition solutions should contact their patients to alert them to discontinue using the solutions and replace them with ones not compounded with the affected lot. Baxter is contacting customers by email with instructions on how to identify and return the impacted product. Consumers with questions regarding this recall can contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

[Read the current instructions](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-issues-voluntary-nationwide-recall-one-lot-70-dextrose-injection-due-potential-presence)

## Before changing a medicine

Follow urgent instructions in the current official recall notice. Speak to your pharmacist or prescriber before stopping or changing a prescribed medicine.

Talk to your doctor or pharmacist if you have questions or concerns about your medicine. [FDA medication recall guidance](https://www.fda.gov/drugs/drug-recalls/understanding-drug-recalls-what-know-and-what-do)

## Related records

[Medications records](https://isitonrecall.com/category/medications/) [Baxter International Inc. records](https://isitonrecall.com/brand/baxter-international-inc/)